Cabazitaxel/Abiraterone Yields PFS Improvement in mCRPC
A significant reduction in disease progression or death was noted when cabazitaxel (Jevtana), abiraterone acetate (Zytiga), and prednisone were used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and who have previously been …